Source-grounded facts extracted from Schrodinger, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Mannix Aklian departed as Chief Commercial Officer, Global Head of Software Sales and Marketing at Schrodinger, Inc..
“On June 5, 2026, following the previously disclosed separation of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing of Schrödinger, Inc. (the “Company”), the Company entered into a transition, separation and release of claims agreement (the “Separation Agreement”) with Mr. Aklian, which confirms the terms of his separation from the Company.”
Paul Davie was appointed as Chief Commercial Officer, Global Head of Software Sales and Marketing at Schrodinger, Inc..
“Paul Davie, the Company’s former Executive Vice President, Sales is returning to the Company as interim Chief Commercial Officer, Global Head of Software Sales and Marketing, while the Company conducts a search for a permanent replacement.”
Mannix Aklian departed as Chief Commercial Officer, Global Head of Software Sales and Marketing at Schrodinger, Inc..
“On May 18, 2026, Mannix Aklian ceased to serve as Schrödinger, Inc.’s (the “Company”) Chief Commercial Officer, Global Head of Software Sales and Marketing, effective immediately.”
Schrodinger, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 5, 2026, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
Richie Jain was appointed as Executive Vice President and Chief Financial Officer at Schrodinger, Inc..
“On May 16, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Schrödinger, Inc. (the “Company”) appointed Richie Jain as Executive Vice President and Chief Financial Officer and Treasurer of the Company, effective immediately.”
Schrodinger, Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million, net income $(54.7) million. Guidance reaffirmed.
“expressly incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports First Quarter 2024 Financial Results First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for”
Schrodinger, Inc. amended Amended and Restated Sales Agreement with Leerink Partners LLC valued at up to $250.0 million (effective 2024-02-28).
“On February 28, 2024, Schrödinger, Inc., a Delaware corporation (the “ Company ”), entered into an Amended and Restated Sales Agreement (the “ Sales Agreement ”) with Leerink Partners LLC, as agent (“ Leerink Partners ”), pursuant to which the Company may offer and sell shares of its common stock, $0.01 par value per share (the “ Common Stock ”), from time to time through Leerink Partners.”
Schrodinger, Inc. reported year ended December 31, 2023 results: revenue $216.7 million, net income $40.7 million.
“Total revenue for the full year increased 19.7% to $216.7 million”
Schrodinger, Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $74.1 million, net income $30.7 million net loss.
“Total revenue for the fourth quarter increased 30.4% to $74.1 million”
Schrodinger, Inc. reported the third quarter ended September 30, 2023 results: revenue $42.6 million, net income $71.4 million. Guidance reaffirmed.
“incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports Third Quarter 2023 Financial Results Delivers Third Quarter Total Revenue of $42.6 Million; Maintains Full-Year 2023 Revenue Guidance Continued Progress for SGR-1505, Healthy Volunteer Data Expected in Fourth Quarter of 2023 Phase 1 Study Initiated for SGR-2921;”
Schrodinger, Inc. reported second quarter ended June 30, 2023 results: revenue $35.2 million, net income $4.3 million. Guidance raised.
“Quarter 2023 Financial Results Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505 Delivers Second Quarter Total Revenue of $35.2 Million Raises 2023 Software Revenue Guidance and Reduces Drug Discovery Guidance New York, August 2, 2023 – Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform”
Schrodinger, Inc. reported the quarter ended on June 30, 2023 results: revenue $35.2 million, net income $4.3 million. Guidance raised.
“Quarter 2023 Financial Results Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505 Delivers Second Quarter Total Revenue of $35.2 Million Raises 2023 Software Revenue Guidance and Reduces Drug Discovery Guidance New York, August 2, 2023 – Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform”
Schrodinger, Inc. shareholders approved Ratification of the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 at the 2023-06-15 meeting.
“Proposal 3 – Ratification of the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Schrodinger, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-06-15 meeting.
“Proposal 2 – Advisory Vote on Executive Compensation The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Schrodinger, Inc. shareholders approved Election of Three Class III Directors at the 2023-06-15 meeting.
“Proposal 1 – Election of Three Class III Directors The Company’s stockholders elected Richard A. Friesner, Rosana Kapeller-Libermann and Gary Sender as Class III directors of the Board, each to serve for a three-year term expiring at the 2026 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified.”
Schrodinger, Inc. reported first quarter 2023 results: revenue $64.8 million, net income $129.1 million. Guidance reaffirmed.
“by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports Strong First Quarter 2023 Financial Results Delivered First Quarter Total Revenue of $64.8 Million, Driven by Strong Drug Discovery Revenue of $32.6 Million Reports First Subjects Enrolled in Both Ongoing Phase 1 Study of MALT1 Inhibitor SGR-1505 and Newly Initiated Phase 1”
Schrodinger, Inc.: Amended and restated bylaws effective immediately on April 12, 2023, with changes including universal proxy rule compliance, removal of inoperative written consent provision, and emergency board meeting provisions (effective 2023-04-12).
“On April 12, 2023, the Board of Directors (the “Board”) of Schrödinger, Inc. (the “Company”) approved an amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.”
Schrodinger, Inc. reported Fiscal year ending December 31, 2023 results: revenue Software revenue growth expected to be in the range of 13 to 17 percent; Drug discovery revenue expected to range from $. Guidance initiated.
“• Software revenue growth is expected to be in the range of 13 to 17 percent • Drug discovery revenue is expected to range from $70 million to”
Schrodinger, Inc. reported Twelve months ended December 31, 2022 results: revenue Total revenue $181.0 million, net income Net loss $(149.2) million.
“Total revenue for the full year increased 31% to $181.0 million, compared to $137.9 million for 2021. • Software revenue for the full year 2022 increased 20% to $135.6 million, compared to $113.2 million for 2021, with multi-year agreements making a similar contribution to reported revenue to the contribution in 2021 and 2020. • Drug discovery revenue for the full year was $45.4 million for the full year 2022, compared to $24.7 million for 2021. • Software gross margin was 78% for the full year, compared to 77% for 2021. • Operating expenses were $247.8 million for the full year, compared to $177.1 million for 2021. • Other expense, which includes gains/loss on equity investments, changes in fair value of such investments and interest income/expense, was $2.3 million for the full year, compared to other income of $10.6 million for 2021. • Net loss for the full year was $149.2 million, compared to $101.2 million for 2021.”
Schrodinger, Inc. updated its the fiscal year ending December 31, 2022 guidance (reaffirmed).
“Total revenue is now expected to range from $167 million to $175 million, compared to the prior expectation of $161 million to $181 million.”
Schrodinger, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 3, 2022, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
Jenny Herman changed role as Interim Principal Financial Officer at Schrodinger, Inc..
“As a result of Dr. Porges’ appointment as Chief Financial Officer, Jenny Herman, the Company’s Senior Vice President, Finance and Corporate Controller, will cease to serve as the Company’s interim principal financial officer.”
Geoffrey Porges was appointed as Executive Vice President and Chief Financial Officer at Schrodinger, Inc..
“On August 16, 2022, the Board of Directors (the “Board”) of Schrödinger, Inc. (the “Company”) appointed Geoffrey Porges as Executive Vice President and Chief Financial Officer of the Company, effective upon the commencement of his employment with the Company on August 18, 2022”
Arun Oberoi was elected as member of the Board at Schrodinger, Inc..
“On May 17, 2022, the Board of Directors (the “Board”) of Schrödinger, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Arun Oberoi as a member of the Board, effective immediately.”
Joel Lebowitz retired as Chief Financial Officer and Treasurer at Schrodinger, Inc..
“On February 28, 2022, following the previously disclosed retirement of Joel Lebowitz as Chief Financial Officer and Treasurer of Schrödinger, Inc. (the “Company”), the Company entered into a transition, separation and release of claims agreement (the “Transition Agreement”) with Mr. Lebowitz, which confirms the terms of his retirement from the Company, effective as of February 28, 2022”
Jenny Herman was appointed as interim principal financial officer at Schrodinger, Inc..
“On December 18, 2021, the Board of Directors of the Company appointed Jenny Herman as the interim principal financial officer, effective as of March 1, 2022.”
Joel Lebowitz departed as Chief Financial Officer at Schrodinger, Inc..
“On December 16, 2021, Joel Lebowitz notified Schrödinger, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of February 28, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.